GlassScriptPhysician profile
Yolanda Lawson
NPI 1952071912
$10,131.13
in general payments reported to CMS, 2019-2025
50 companies · $1,949 in 2025
The $1,949 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $343 · 2022: $2,966 · 2023: $2,468 · 2024: $2,405 · 2025: $1,949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,748 · Education: $73.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,748.14 |
| Education | $73.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,178.02 | 2022-2025 | Jynarque, Rexulti, Nuedexta |
| Astrazeneca Pharmaceuticals LP | $1,126.14 | 2021-2025 | Farxiga, Airsupra, Lokelma |
| Abbvie INC. | $959.46 | 2022-2025 | |
| Novo Nordisk INC | $718.93 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $625.16 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $509.34 | 2022-2025 | Korlym |
| Amgen INC. | $509.03 | 2022-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $451.18 | 2022-2025 | Jardiance, Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $442.28 | 2021-2024 | Glassia |
| Abbott Laboratories | $430.83 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $404.45 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $375.63 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $218.34 | 2021-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $197.60 | 2022-2025 | Verquvo, Belsomra |
| Sanofi-Aventis U.S. LLC | $192.78 | 2022-2023 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yolanda Lawson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.